Atara Biotherapeutics
ATRA
82 hedge funds and large institutions have $441M invested in Atara Biotherapeutics in 2017 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 30 increasing their positions, 23 reducing their positions, and 11 closing their positions.
8,940% more call options, than puts
Call options by funds: $452K | Put options by funds: $5K
30% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 23
22% more capital invested
Capital invested by funds: $360M → $441M (+$80.7M)
0.06% less ownership
Funds ownership: 3.54% → 3.48% (-0.06%)
4% less funds holding
Funds holding: 85 → 82 (-3)
27% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 11
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$10.4M |
| 2 |
Morgan Stanley
New York
|
+$6.8M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
+$2.35M |
| 4 |
Neuberger Berman Group
New York
|
+$2.22M |
| 5 |
BM
Bridger Management
New York
|
+$1.93M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
-$7.79M |
| 2 |
GTC
Ghost Tree Capital
New York
|
-$4.9M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.56M |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$829K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$510K |
ATRA Hedge Fund Activity: Q3 2017 in Review
82 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Atara Biotherapeutics (ATRA) for Q3 2017, worth a combined $441M — up 22% from $360M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of ATRA and 8 opened new positions — a net loss of 3 holders — while 23 trimmed existing stakes and 30 added.
The largest buyer was ArrowMark Colorado Holdings, adding an estimated $10.4M. The largest seller was RTW Investments, cutting an estimated $7.79M.
- 82 institutional investors held Atara Biotherapeutics (ATRA) as of Q3 2017, down from 85 in Q2 2017.
- Funds reported $441M of Atara Biotherapeutics stock for Q3 2017, up 22% quarter-over-quarter.
- 8 funds opened new Atara Biotherapeutics positions in Q3 2017 and 11 closed out, a net change of -3 holders.
- The largest Atara Biotherapeutics buyer in Q3 2017 was ArrowMark Colorado Holdings, an estimated $10.4M added.
- The largest Atara Biotherapeutics seller in Q3 2017 was RTW Investments, an estimated $7.79M sold.
Based on aggregated 13F filings for Q3 2017.